Tag: Financial

Cybin Reports Fiscal Year 2024 Financial Results and Recent Business Highlights

– Received U.S. Food and Drug Administration (“FDA”) Breakthrough Therapy Designation (“BTD”) for CYB003, its proprietary deuterated psilocybin analog in development for the adjunctive treatment of Major Depressive Disorder (“MDD”) –

– Clinical site selection complete for Phase 3 multinational

Back To Top